MedTrace Logo

Baden Prevention and Reduction of Incidence of Postoperative Delirium Trial

NCT02433041 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2019-01-23

No results posted yet for this study

Summary

The purpose of this study is to find out whether postoperative delirium can be more properly prevented by the combination of determined preventive agents in past studies. Further on the investigators measure pre- and postoperative cortisol, neuron specific enolase (NSE) and S-100beta levels.

Conditions

  • Postoperative Delirium

Interventions

DRUG

Haloperidol

Haloperidol 0.005mg/kg at induction of anesthesia

DRUG

Ketamine

Ketamine 1mg/kg at induction of anesthesia to test its power to prevent postoperative delirium

DRUG

Haloperidol + Ketamine

Haloperidol 0.005mg/kg + Ketamine 1mg/kg at induction of anesthesia to test their power to prevent postoperative delirium if given together

DRUG

Saline solution (NaCl 0.9%)

Placebo being used in one of the four groups

Sponsors & Collaborators

  • Kantonsspital Baden

    collaborator OTHER

  • University Hospital, Basel, Switzerland

    lead OTHER

Principal Investigators

  • Alexa Hollinger, MD · University Hospital, Basel, Switzerland

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2018-12-21
Completion
2018-12-21

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02433041 on ClinicalTrials.gov